



SHAREABLE PDF

Blood eosinophil counts in COPD patients compared to controls

Umme Kolsum¹, Thomas Southworth^{1,2}, Natalie Jackson² and Dave Singh^{1,2}

Affiliations: ¹The University of Manchester, Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK. ²The Medicines Evaluation Unit, The Langley Building, Wythenshawe Hospital, Manchester, UK.

Correspondence: Umme Kolsum, The University of Manchester, Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK. E-mail: ukolsum@meu.org.uk



@ERSpublications

Blood eosinophil counts are increased in COPD patients compared to healthy controls <http://bit.ly/2ML6pzZ>

Cite this article as: Kolsum U, Southworth T, Jackson N, *et al.* Blood eosinophil counts in COPD patients compared to controls. *Eur Respir J* 2019; 54: 1900633 [<https://doi.org/10.1183/13993003.00633-2019>].

This single-page version can be shared freely online.

To the Editor:

In patients with COPD, blood eosinophil counts can predict the effects of inhaled corticosteroids (ICS) on exacerbation rates [1–4]. Blood eosinophil counts are now recommended by the Global initiative for the management of Obstructive Lung Disease (GOLD) as a biomarker to help guide ICS use in clinical practice [5].

